Analyzing bioAffinity Technologies (BIAF) and Its Peers

bioAffinity Technologies (NASDAQ:BIAF) is one of 39 publicly-traded companies in the “Commercial physical research” industry, but how does it weigh in compared to its competitors? We will compare bioAffinity Technologies to similar businesses based on the strength of its risk, earnings, dividends, analyst recommendations, valuation, profitability and institutional ownership.

Valuation & Earnings

This table compares bioAffinity Technologies and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
bioAffinity Technologies	$2.53 million	-$7.94 million	-3.23
bioAffinity Technologies Competitors	$1.55 billion	$101.44 million	-0.65

bioAffinity Technologies’ competitors have higher revenue and earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares bioAffinity Technologies and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-313.34%	-107.20%	-84.10%
bioAffinity Technologies Competitors	-249.68%	-18.55%	-11.34%

Volatility and Risk

bioAffinity Technologies has a beta of 3.93, meaning that its share price is 293% more volatile than the S&P 500. Comparatively, bioAffinity Technologies’ competitors have a beta of 6.02, meaning that their average share price is 502% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for bioAffinity Technologies and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	0	0	0	0	N/A
bioAffinity Technologies Competitors	50	814	1297	31	2.60

As a group, “Commercial physical research” companies have a potential upside of 11.04%. Given bioAffinity Technologies’ competitors higher possible upside, analysts clearly believe bioAffinity Technologies has less favorable growth aspects than its competitors.

Insider and Institutional Ownership

1.6% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 52.6% of shares of all “Commercial physical research” companies are owned by institutional investors. 44.3% of bioAffinity Technologies shares are owned by company insiders. Comparatively, 16.7% of shares of all “Commercial physical research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

bioAffinity Technologies competitors beat bioAffinity Technologies on 9 of the 10 factors compared.

About bioAffinity Technologies

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.